Expertise in
8
conditions

Florian Lordick

Leipzig, SN, DE 
Expertise in
8
conditions
Leipzig, SN, DE 

Overview

Florian Lordick practices practicing medicine in Leipzig, Germany.

Mr. Lordick is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Stomach Cancer, Esophageal Cancer, Gastroesophageal Junction Cancer, Gastrectomy, and Endoscopy.

He is actively involved in clinical research, co-authoring 393 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Leipzig, SN, Germany
Other Locations
Detmold, NW, Germany
Jena, TH, Germany
Neuherberg, BY 85764, Germany
Hannover, NI, Germany
Braunschweig, NI, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug, Radiation
Study Drugs: Gemcitabine, FOLFIRINOX
Study Phase: Phase 3
Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer SPECTAcolor
Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer SPECTAcolor
Enrollment Status: Completed
Publish Date: July 07, 2022
Intervention Type: Genetic
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.
Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.
Enrollment Status: Unknown
Publish Date: September 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

393 Total Publications

Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions.
Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions.
Journal: ESMO gastrointestinal oncology
Published: September 03, 2026

Frequently Asked Questions about Florian Lordick

Is Florian Lordick a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Florian Lordick is classified as an Elite expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Florian Lordick participate in research or clinical trials?

Yes. Florian Lordick has published 393 articles and abstracts on conditions like Stomach Cancer. You can view a list of Florian Lordick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lordick's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile